Nicoletta Loggia
Direttore Tecnico/Scientifico/R&S presso ORCHARD THERAPEUTICS PLC
Posizioni attive di Nicoletta Loggia
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ORCHARD THERAPEUTICS PLC | Direttore Tecnico/Scientifico/R&S | 09/09/2021 | - |
| CANDEL THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 07/06/2023 | - |
| Independent Dir/Board Member | 07/06/2023 | - |
Storia della carriera di Nicoletta Loggia
Formazione di Nicoletta Loggia
| University of Pavia | Doctorate Degree |
Statistiche
Distribuzione geografica
| Regno Unito | 2 |
| Italia | 2 |
| Stati Uniti | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| CANDEL THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Orchard Therapeutics Plc
 Orchard Therapeutics Plc Pharmaceuticals: MajorHealth Technology Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Nicoletta Loggia
- Esperienza
